SOBI lifts 2026 revenue guidance after stronger third-quarter sales
Swedish Orphan Biovitrum reported third-quarter revenue growth and raised its full-year 2026 revenue guidance, while launch and R&D spending increased.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, revenue at Swedish Orphan Biovitrum (SOBI) rose 16% at constant exchange rates in the third quarter, and 26% excluding Beyfortus royalties. On the back of these figures, the company raised its revenue guidance for fiscal 2026.
Strong growth across products and regions was partly offset by higher spending on launching new medicines and on research and development. Uncertainty around RSV royalties remains an additional factor.
why it matters
Investors will focus on two signals: the raised guidance and revenue growth excluding Beyfortus royalties, which point to momentum in the core business and less dependence on a single income source. Still, higher launch and R&D costs and the unclear RSV picture limit how far the good results can lift the shares.
market impact
SOBI shares: strong results and higher guidance support the stock, while costs and RSV uncertainty weigh
- SOBI shares mixed — revenue growth and higher guidance offset by rising costs and RSV uncertainty
tags
instruments
sources
- SOBI: Strong Q3 growth raised revenue guidance, while RSV uncertainty and launch investment remain key offsets — TradingView, 27 October 2026 at 23:48 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗